Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

NCT01460498 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Azacitidine (AZA)
DRUG: Tyrosine kinase inhibitor (TKI)
DRUG: Azacitidine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]